Success Metrics

Clinical Success Rate
75.8%

Based on 160 completed trials

Completion Rate
76%(160/211)
Active Trials
656(64%)
Results Posted
93%(149 trials)
Terminated
51(5%)

Phase Distribution

Ph phase_3
103
10%
Ph not_applicable
110
11%
Ph phase_4
4
0%
Ph phase_2
438
42%
Ph early_phase_1
40
4%
Ph phase_1
271
26%

Phase Distribution

311

Early Stage

438

Mid Stage

107

Late Stage

Phase Distribution966 total trials
Early Phase 1First-in-human
40(4.1%)
Phase 1Safety & dosage
271(28.1%)
Phase 2Efficacy & side effects
438(45.3%)
Phase 3Large-scale testing
103(10.7%)
Phase 4Post-market surveillance
4(0.4%)
N/ANon-phased studies
110(11.4%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

61.3%

160 of 261 finished

Non-Completion Rate

38.7%

101 ended early

Currently Active

656

trials recruiting

Total Trials

1,032

all time

Status Distribution
Active(716)
Completed(160)
Terminated(101)
Other(55)

Detailed Status

Recruiting399
Active, not recruiting257
Completed160
Not yet recruiting59
Terminated51
Withdrawn50

Development Timeline

Analytics

Development Status

Total Trials
1032
Active
656
Success Rate
75.8%
Most Advanced
Phase 4

Trials by Phase

Early Phase 140 (4.1%)
Phase 1271 (28.1%)
Phase 2438 (45.3%)
Phase 3103 (10.7%)
Phase 44 (0.4%)
N/A110 (11.4%)

Trials by Status

suspended212%
active_not_recruiting25725%
enrolling_by_invitation10%
terminated515%
not_yet_recruiting596%
completed16016%
unknown343%
withdrawn505%
recruiting39939%

Recent Activity

Clinical Trials (1,032)

Showing 20 of 1,032 trialsScroll for more
NCT03634241Phase 2

Pembrolizumab in Preventing Lung Cancer in Patients With Stage I-II Non-Small Cell Lung Cancer or High-Risk Pulmonary Nodules, the IMPRINT-Lung Study

Completed
NCT05638295Phase 2

Testing the Use of AMG 510 (Sotorasib) and Panitumumab as a Targeted Treatment for KRAS G12C Mutant Solid Tumor Cancers (A ComboMATCH Treatment Trial)

Recruiting
NCT06649812Phase 2

Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma

Recruiting
NCT05828069Phase 2

A Study With Tovorafenib (DAY101) as a Treatment Option for Progressive, Relapsed, or Refractory Langerhans Cell Histiocytosis

Recruiting
NCT06317662Phase 2

Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

Recruiting
NCT06980038Phase 2

Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer

Recruiting
NCT07224100Phase 2

Dose-Adjusted EPOCH With or Without Rituximab Plus Ponatinib for the Treatment of Newly-Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia/Lymphoma

Recruiting
NCT04665739Phase 2

Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors

Recruiting
NCT06568172Phase 3

Testing the Addition of an Immunotherapy Drug, Cemiplimab (REGN2810), Plus Surgery to the Usual Surgery Alone for Treating Advanced Skin Cancer

Recruiting
NCT07061977Phase 3

Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer

Recruiting
NCT07349771Phase 2

Axatilimab Plus Standard of Care Therapy for the Prevention of Graft Versus Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Hematologic Cancer, ABRAXAS Trial

Not Yet Recruiting
NCT05564377Phase 2

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

Recruiting
NCT02615275Not Applicable

Bioelectrical Impedance Analysis in Estimating Body Composition in Patients With Stage I-IV Head and Neck Cancer Undergoing Radiation Therapy

Active Not Recruiting
NCT05256225Phase 3

Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma

Recruiting
NCT03418038Phase 2

Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia

Recruiting
NCT06179303Phase 2

Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer

Recruiting
NCT07003295Phase 2

Testing the Anti-cancer Drug, Glofitamab, in Patients With Mantle Cell Lymphoma (A Type of Blood Cancer) Whose Disease Returned After CAR-T Cell Therapy

Recruiting
NCT03866382Phase 2

Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

Recruiting
NCT04671667Phase 2

Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma

Recruiting
NCT06015880Phase 1

Testing the Combination of Anti-cancer Drugs Mosunetuzumab, Polatuzumab Vedotin, and Lenalidomide for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Recruiting

Drug Details

Intervention Type
PROCEDURE
Total Trials
1,032